Hans Jürgen Hoffmann

Novel Approaches and Perspectives in Allergen Immunotherapy

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearchpeer-review


  • Hans Jürgen Hoffmann
  • Erkka Valovirta, Department of Lung Diseases and Clinical Immunology, Univ of Turku.
  • ,
  • Oliver Pfaar, Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, D-68167, Mannheim, Germany.
  • ,
  • Philippe Moingeon, Research and Development, StallergenesGreer, 6 Rue Alexis de Tocqueville, 92183, Antony Cedex, France.
  • ,
  • Johannes Martin Schmid
  • Søren Helbo Skaarup
  • Lars-Olaf Cardell, Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm.
  • ,
  • Kim Simonsen, Chief Development Officer. Anergis SA. BioPole III - Route de la Corniche 9B, CH-1066, Epalinges, Switzerland.
  • ,
  • Mark Larche, Clinical Immunology & Allergy and Respirology Divisions, Department of Medicine McMaster University, Hamilton, Ontario, Canada.
  • ,
  • Stephen R Durham, Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London.
  • ,
  • Poul Sørensen

In this review we report on relevant current topics in allergen immunotherapy (AIT) which were broadly discussed during the 1(st) Aarhus Immunotherapy Symposium (Aarhus, Denmark) in December, 2015 by leading clinicians, scientists and industry representatives in the field. The aim of this symposium was to highlight AIT-related aspects of public health, clinical efficacy evaluation, mechanisms, development of new biomarkers and an overview of novel therapeutic approaches. Allergy is a public health issue of high socioeconomic relevance, and development of evidence-based action plans to address allergy as a public health issue ought to be on national and regional agendae. The underlying mechanisms are in the focus of current research that lays the ground for innovative therapies. Standardization and harmonization of clinical endpoints in AIT trials as well as current knowledge about potential biomarkers have substantiated proof of effectiveness of this disease-modifying therapeutic option. Novel treatments like peptide immunotherapy, intralymphatic immunotherapy and use of recombinant allergens herald a new age in which AIT may address treatment of allergy as a public health issue by reaching a large fraction of patients. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalAllergy: European Journal of Allergy and Clinical Immunology
Pages (from-to)1022-1034
Number of pages13
Publication statusPublished - Jul 2017

See relations at Aarhus University Citationformats

ID: 108662269